Navigation Links
Sinovac Schedules 2013 Annual Meeting of Shareholders
Date:7/19/2013

BEIJING, July 19, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2013 Annual Meeting of Shareholders on Wednesday, August 21, 2013 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District, Beijing, PRC. All shareholders of record as of July 3, 2013 will be eligible to vote and are invited to attend.

The primary agenda of the meeting is to approve the re-election of Weidong Yin, Yuk Lam Lo, Simon Anderson, Kenneth Lee and Meng Mei as the Company's directors until the next annual meeting of shareholders and or until their successors are duly elected; approve the audited consolidated financial statements of the Company for the financial year ended December 31, 2012 together with the Report of Independent Registered Public Accounting Firm thereon and the notes thereto; approve the appointment of Ernst &Young Hua Ming LLP as the independent auditor of the Company for the fiscal year ending December 31, 2013 and to authorize the directors of the Company to fix such independent auditor's remuneration.

Sinovac's 2012 annual report and proxy statements, including the Notice of the 2013 Annual General Meeting, are available on the Company's website: http://www.sinovac.com/?optionid=751.

Shareholders of the Company may receive a hard copy of 20-F free of charge upon request. Such request can be made by sending an e-mail to ir@sinovac.com, along with complete contact details and a mailing address.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease).  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9659/9696
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel:  +1-646-536-7028
Email: aestrada@theruthgroup.com

 

 

 


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Appoints New Chief Financial Officer
2. Sinovac Reports Unaudited First Quarter 2013 Financial Results
3. Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines
4. Sinovac to Host Conference Call to Report First Quarter 2013 Unaudited Financial Results
5. Sinovac Appoints Ernst & Young Hua Ming Llp China as External Auditor
6. Sinovac Presents at the UBS Global Healthcare Conference in May 2013
7. Sinovac Files Annual Report on Form 20-F
8. Sinovac EV71 Vaccine Phase III Top-Line Results Presented at 13th Annual World Vaccine Congress & Expo
9. Sinovac Reports Unaudited Third Quarter 2012 Financial Results
10. Sinovac to Host Conference Call to Report Third Quarter 2012 Unaudited Financial Results
11. Sinovac Receives Beijing CDC Tender Award to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... announced the addition of the "Rheumatoid Arthritis Drugs Price Analysis and ... latest research Rheumatoid Arthritis Drugs Price Analysis and Strategies - 2016, provides ... The research answers the following questions: ... attributes? How are they positioned in the Global Rheumatoid Arthritis market? ...
(Date:2/28/2017)... 2017 Medical robots market is projected to ... billion in 2016, growing at a CAGR of 21.1% ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... therapy, technological advancements, increase in funding for medical robots ... growing hospital investments are the key factors driving the ...
(Date:2/28/2017)... , Feb. 27, 2017  Summary This ... understand Syngenta and its partnering interests and activities since ... Description The Partnering Deals and Alliance ... partnering activity of one of the world,s leading life ... prepared upon purchase to ensure inclusion of the most ...
Breaking Medicine Technology:
(Date:2/28/2017)... ... February 28, 2017 , ... ... in North America for the scientific development, healthcare training and clinical application of ... & Scientific Session on September 16-17 in Greenville, SC at the Bon Secours ...
(Date:2/28/2017)... , ... February 28, 2017 , ... ... Inc., a healthcare automation intelligence company based in New York. , “Ensuring an ... the provider’s workflow remains unaltered. Those two fundamental reasons are the reasons this ...
(Date:2/27/2017)... ... February 27, 2017 , ... It’s ... strength, which often leads to a host of health issues, including urinary incontinence. ... Geriatrics Society discovered that good overall muscle strength in older women, particularly ...
(Date:2/27/2017)... ... February 27, 2017 , ... The threat of nuclear warfare ... for a company involved in the underground testing of nuclear weapons. Years later, when ... Expendable Workers of the Cold War Nuclear Testing,” Clayton exposes the critical decisions made ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines ... despite scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases ... Kenneth B. Liegner, M.D. has compiled into a single volume a compelling argument that ...
Breaking Medicine News(10 mins):